Cure My Disease

Don't miss your cure!

 Log in / Sign up

Taiwan launches genetic mapping of brain tumors to unlock new treatments

NCT ID NCT05622409

Knowledge-focused Sponsor: National Health Research Institutes, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study aims to collect and analyze genetic information from 250 adults in Taiwan diagnosed with diffuse gliomas, a type of brain tumor. Researchers will use tumor tissue and blood samples to identify genetic patterns. The goal is to better understand why these tumors are so hard to treat and to find clues for future therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors understand the genetic makeup of brain tumors in Taiwanese patients, potentially pointing toward more personalized treatments in the future.
What could go wrong
This is an observational registry study, not a treatment trial. It will not directly benefit participants and may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Arm 1: (Newly diagnosis arm): Anticipated 100 patients. Arm 2: IDH expression (N=83 for IDH-mutant and N=82 for IDH-wild type) Arm 3:Recurrent and paired samples (N=10).

Ages

20 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pathological confirmation or suggestion of adult-type diffuse gliomas A. Diagnosis includes glioblastoma, astrocytoma, oligodendrocytoma that is listed in ATDG category per WHO criteria. B. Gliomas that are preferred as ATDGs from pathological and clinical views, but not given for confirmed diagnosis. 2. Willingness to provide archival or newly obtained tumor tissues for current study proposal. 3. Age equal or more than 20 years old (inform consent). 4. Life expectancy more than 3 months. 5. Patients fully understand the protocol with the willingness to have regular follow-up. 6. Additional criteria for individual arms A. \[Arm 1\] Within 2 months after surgery for primary tumor. B. \[Arm 2\] Total resection of primary tumors with tissue samples available for test. C. \[Arm 3\] (1) Total resection of primary tumors with the paired primary and recurrent tissue samples available for test. (2) IDH test suggesting wild-type. Exclusion Criteria: 1. Gliomas diagnosed or preferred as other categories than ATDGs, such as pediatric-type diffuse gliomas, circumscribed astrocytic gliomas, and others. 2. Inability to cooperate by providing a complete medical history. 3. Patients disagree to provide archived tumor samples. 4. Undesirable compliance. 5. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary malignant brain tumors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary malignant brain tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHANG GUNG MEMORIAL HOSPITAL, Linkou

    RECRUITING

    Taoyuan, Taiwan

  • China Medical University Hospital

    RECRUITING

    Taichung, Taiwan

  • Kaohsiung Chang Gung Memorial Hospital

    RECRUITING

    Kaohsiung City, Taiwan

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, Taiwan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

  • Shuang Ho Hospital

    RECRUITING

    New Taipei City, Taiwan

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, Taiwan

  • Taipei Medical University -Ministry of Health and Welfare Shuang-Ho Hospital

    RECRUITING

    Taipei, Taiwan